Navigation Links
Novo Nordisk Wins Design Award for NovoTwist(TM) Needle
Date:10/25/2009

COPENHAGEN, October 26 /PRNewswire/ -- Novo Nordisk has been awarded a Good Design Award(TM)(1) for NovoTwist(TM), the new needle designed for use with the insulin delivery device FlexPen(R). The needle, which has a simple 'just twist' attachment and detachment, makes injection easier for people with diabetes.

The Good Design Award(TM) (also known as G-Mark Award)(1) from the Japan Industrial Design Promotion Organization is a mark of true quality and gives recognition to the uniqueness of NovoTwist(TM). Nearly 3,000 entries were narrowed down by the judging panel and NovoTwist(TM) was selected for an award in the 'Society - Medical Equipment' section.(1) Previous winners of the Good Design Award(TM) include Apple, Toshiba, Toyota and Nintendo. The Good Design Award(TM)(1) highlights the unique design features of NovoTwist(TM). The judges specifically commented that "Conventional screw thread needles can be difficult to attach and detach, especially for the elderly, as limited manual dexterity and hand strength make the circular motion of screw attachment/detachment challenging. NovoTwist(TM) has solved this problem with a simple functional design with a push-and- twist needle attachment/detachment system."

When used with FlexPen(R), three out of four patients prefer NovoTwist(TM) to conventional needles,(2) and patients find NovoTwist(TM) easier to use, less timeconsuming and more user-friendly than conventional needles.(2,3) These benefits may be important to people with diabetes who seek easier and more discreet methods of self-administering insulin.

"Given the general anxiety that some people with diabetes can suffer when using any injection device, the new developments with NovoTwist(TM) are a big step forward in terms of user-friendliness," says diabetes nurse Barbel Sommavilla (Diabetes Education Center, Salzburg, Austria) who was involved in a key study assessing patients' preference for insulin pe
'/>"/>

SOURCE Novo Nordisk
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes
2. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
3. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
4. Dartmouth Medical School Faculty Member and Anesthesiologist Invents Revolutionary Catheter System Designed to Increase Rate of Successful IV Insertions by 75 Percent
5. SEI Defined Benefit Client Recognized With Leading Plan Design Award
6. Ethicon Endo-Surgery Wins Prestigious International Design Award for Innovative Development of HARMONIC FOCUS(TM)
7. Cortheras Relaxin Receives FDA Fast Track Designation for the Treatment of Acute Heart Failure
8. Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy
9. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
10. Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... -- Whole-cell pertussis vaccines were more effective at protecting against ... outbreak, according to a new Kaiser Permanente study published ... DTwP, were available from the 1940s to 1990s, but ... the development of acellular pertussis vaccines, which are also ... United States had switched from whole-cell to ...
(Date:5/18/2013)... -- Although colonoscopy exams prevent many colon cancer deaths ... for detecting colorectal cancers 2 , the procedure is ... EndoChoice ® Inc. today unveiled research that shows ... of this procedure and greatly reduces the number of ... clinical trial results and featuring the Fuse system that ...
(Date:5/18/2013)... 18, 2013 Faruqi & Faruqi, LLP, ... potential securities fraud at AVEO Pharmaceuticals, Inc. ("AVEO" ... http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) The investigation ... violated federal securities laws by issuing materially false ... drug trials for Tivopath (tivozanib) (titled "TIVO-1").  Specifically, ...
Breaking Medicine Technology:Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 2Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 3Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 4New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 2New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 3Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2
... 26, 2007 - Aeolus,Pharmaceuticals, Inc. (OTCBB:AOLS) announced ... issue of the Journal of Neuroscience a ... and National Jewish,Medical and Research Center demonstrating ... AEOL 11207, demonstrated,neuroprotection in an animal model ...
... adding Diovan to conventional therapy , , , Study ... , , BASEL,Switzerland, April 27, 2007 ... published today in The Lancet[1], show that,adding the blood ... 39% reduction in,cardiovascular events and a 40% reduction in ...
Cached Medicine Technology:Study Demonstrating Aeolus Compound's Neuroprotection in,Parkinson's Disease Published in the Journal of Neuroscience 2Study Demonstrating Aeolus Compound's Neuroprotection in,Parkinson's Disease Published in the Journal of Neuroscience 3Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 2Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 3Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 4Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 5Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 6Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 7
(Date:5/20/2013)... Adeptia Inc., a leading ... process integration solutions, today announced the availability ... solution. Version 6.0 is the only ... business processes involving data access, validation, transformation, ... interaction for real-time decision-making and exception-handling. The ...
(Date:5/20/2013)... Although many hospital intensive care units have a ... outcomes, new research suggests this may have no ... teaching hospitals in the United States and three-quarters ... in the ICU, the practice may unnecessarily increase ... with fewer resources, the study authors said. ...
(Date:5/20/2013)... NY (PRWEB) May 20, 2013 In ... of the numerous scientific accomplishments achieved at The ... group of female scientists, Advancing Women in Science ... breakfast on May 17. Scientists, educators, business and ... celebrate excellence and achievements of women in science. ...
(Date:5/20/2013)... toothpaste that transforms the sweet flavor of orange juice ... mysterious sensory phenomenon in colorful, animated detail ... award-winning Bytesize Science video series at ... scientific society, explains that the mainstay ingredients in toothpaste ... for short. When you brush your teeth, SLS produces ...
(Date:5/20/2013)... 2013) Wolters Kluwer Health is ... Wilkins (LWW) published journals won 13 ASHPE awards ... member articles and publications for editorial, design, print ... honor to be recognized year after year for ... the industry with quality, depth, and impact," said ...
Breaking Medicine News(10 mins):Health News:Adeptia Announces New Release of Enterprise Business Integration Solution 2Health News:Adeptia Announces New Release of Enterprise Business Integration Solution 3Health News:Nighttime Docs at ICUs Don't Boost Patient Outcomes: Study 2Health News:North Shore-LIJ's Feinstein Institute Celebrates Women in Science During National Women’s Health Week 2Health News:North Shore-LIJ's Feinstein Institute Celebrates Women in Science During National Women’s Health Week 3Health News:Wolters Kluwer Health receives 13 awards from the ASHPE 2
... of Charity Health System Bargaining in Bad Faith, ... operated throughout California by the Daughters of,Charity Health System ... Caregivers represented by SEIU United Healthcare Workers-West have been,bargaining ... But,management has refused to make any economic proposals, and ...
... WAKEFIELD, MA, Aug. 15 /PRNewswire-FirstCall/ - NUCRYST,Pharmaceuticals, a ... and inflammation, today announced that on August 14, ... stating that, for the last,30 consecutive trading days, ... market value of publicly held shares ("MVPHS") of ...
... YORK, Aug. 15 The Hereditary Disease Foundation,(HDF) ... Administration has,approved Xenazine, or tetrabenazine, for the treatment ... a major cause of disability and death in ... mere inconvenience; it can,prevent Huntington,s disease patients from ...
... Food and Drug Administration today approved tetrabenazine, the first ... treat Huntington,s disease, a fatal, inherited neurodegenerative disorder for ... eight months after an advisory panel unanimously voted to ... the disease. , The drug is already widely used ...
... in a dangerously abnormal way, a series of death signals ... research to appear in the August 15 issue of ... a way in mice to amplify the signals that tell ... that normally helps cells to avoid self-destruction. , The work, ...
... , ... London, UK (PRWEB) August 15, 2008 -- X Factor star and mother of ... [MYA Cosmetic Surgery]. The 36 year old, who is well known ... MYA and in total has lost 6 inches from her waist, 4 inches ...
Cached Medicine News:Health News:NUCRYST Receives Deficiency Notice from NASDAQ 2Health News:NUCRYST Receives Deficiency Notice from NASDAQ 3Health News:FDA approves first drug for Huntington's disease 2Health News:FDA approves first drug for Huntington's disease 3Health News:FDA approves first drug for Huntington's disease 4Health News:By amplifying cell death signals, scientists make precancerous cells self-destruct 2Health News:X Factor's Niki Evans Amazing Cosmetic Surgery Success 2Health News:X Factor's Niki Evans Amazing Cosmetic Surgery Success 3
... optimize the accuracy and precision of Finnpipettes. ... widely recognized by customers throughout the world. ... the years and now covers a full ... filter tips, certified pure tips, stepper tips ...
... Finntips have been designed to optimize the ... of our tip products is widely recognized ... range has been extended over the years ... standard and special tips including filter tips, ...
... when presented in convenient, steady, Tipack ... pick up directly from the rack. ... tips are loaded without manual intervention. ... security sticker. Fully autoclavable, Tipacks are ...
... Finntips have been designed to optimize ... quality of our tip products is widely ... Finntip range has been extended over the ... of standard and special tips including filter ...
Medicine Products: